Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients

BACKGROUND: Following the PALOMA-3 study results, the combination of palbociclib, a CDK4/6 inhibitor, with fulvestrant, a selective estrogen receptor degrader, has become a standard therapy in women with estrogen receptor-positive (ER+) HER2-negative (HER2−) metastatic breast cancer (MBC). Palbocicl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res
Main Authors: Darrigues, Lauren, Pierga, Jean-Yves, Bernard-Tessier, Alice, Bièche, Ivan, Silveira, Amanda Bartolini, Michel, Marc, Loirat, Delphine, Cottu, Paul, Cabel, Luc, Dubot, Coraline, Geiss, Romain, Ricci, Francesco, Vincent-Salomon, Anne, Proudhon, Charlotte, Bidard, François-Clément
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7937332/
https://ncbi.nlm.nih.gov/pubmed/33676547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-021-01411-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados